BusinessUpdated 26 min ago
Biocon secures USFDA approval for Pebrilzo, its fifth cancer biosimilar

Biocon also said it has secured a global settlement and licence agreement with Genentech, allowing Pebrilzo's earliest licensed US launch in 2028.
Continue reading on Business Standard
Read full story Hello Headlines links you to the original publisher for the full story.



